Please assess the completion status of the following clinical trial:

Trial Title: Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent prior to trial participation.~2. Human immunodeficiency virus-1 infected males or females \>=18 years of age.~3. Screening genotypic resistance report indicating both of the following:~   * at least one primary protease mutation at the following sites 30N, 46I/L, 48V, 50V, 82A/F/L/T, 84V or 90M , and~  * no more than two protease mutations on codons 33, 82, 84, or 90.~4. At least 3 consecutive months experience taking antiretrovirals from each of the classes of Nucleoside reverse transcriptase inhibitor(s), Non-nucleoside reverse transcriptase inhibitor(s), and Protease inhibitor(s) at some point in treatment history,~   * with at least 2 Protease inhibitor-based regimens (minimum 3 months of exposure of each), one of which must be part of the current regimen, and~  * current Protease inhibitor-based antiretroviral medication regimen for at least 3 months prior to randomisation.~5. Human immunodeficiency virus-1 viral load \>=1000 copies/mL at screening.~6. Acceptable screening laboratory values that indicate adequate baseline organ function. Laboratory values are considered to be acceptable if the following apply:~   * Total cholesterol \<=400 mg/dl or 10,36 mm/L.~  * Total triglycerides \<=750 mg/dl or 8,5 mm/L.~  * Alanine aminotransferase \<=3x upper limit of normal and aspartate aminotransferase \<=2.5x upper limit of normal.~  * Any Grade gamma-glutamyl transpeptidase is acceptable.~  * Any Grade creatinine kinase is acceptable as long as there is no concurrent myopathy.~  * All other laboratory test values \<= Grade 1(Division of Acquired immune deficiency syndrome, National Institute of Health grading scale).~7. Acceptable medical history, as assessed by the investigator, with chest X-ray and electrocardiogram within 1 year of study participation.~8. Willingness to abstain from ingesting substances during the study which may alter plasma study drug levels by interaction with the cytochrome P450 system.~9. A prior Acquired immune deficiency syndrome-defining event is acceptable as long as it has resolved or the patient has been on stable treatment for at least 2 months (Acquired immune deficiency syndrome related complex is acceptable).~Exclusion Criteria:~1. Antiretroviral medication naïve.~2. Patients on recent drug holiday, defined as off antiretroviral medications for at least 7 consecutive days within the last 3 months.~3. Alanine aminotransferase \>3x upper limit of normal and aspartate aminotransferase \>2.5x upper limit of normal at either screening visit.~4. Female patients of child-bearing potential who:~   * have a positive serum pregnancy test at screening or during the study,~  * are breast feeding~  * are planning to become pregnant, or~  * are not willing to use a barrier method of contraception, or~  * require ethinyl estradiol administration~5. Prior tipranavir use.~6. Use of investigational medications within 30 days before study entry or during the trial. (T-20 \[enfuvirtide\] and Tenofovir (Viread), investigational at the time of writing of this protocol, will be allowed.)~7. Use of immunomodulatory drugs within 30 days before study entry or during the trial (e.g. interferon, cyclosporin, hydroxyurea, interleukin 2).~8. Inability to adhere to the requirements of the protocol, including active substance abuse as assessed by the investigator.~9. In the opinion of the investigator, likely survival of less than 12 months because of underlying disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tipranavir(TPV)/low dose ritonavir(r) (Type: OTHER): None
- Comparator protease inhibitor(CPI)/low dose ritonavir(r) (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete